Insurer And Patient Drug Costs Soared For Top-Sellers Over 6-Year Study
Median out-of-pocket and insurance costs for 49 high-volume brand-name drugs jumped 79% from 2012 to 2017 in a new analysis of 35m individual insurance claims published in JAMA Network. Competition did not correlate to lower costs.
You may also be interested in...
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”
Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.